SOD1 and amyotrophic lateral sclerosis: In this paper, we present the synthesis and in vitro SAR studies of the newly synthesized NU-9 analogues against mutant superoxide dismutase 1 (SOD1) aggregation and the in vitro pharmacological studies that led us to identify 20, a compound with promising anti-aggregation activity, BBB permeability, and a good pharmacological profile, as a candidate for further ALS therapeutic validation.